Amphastar Pharmaceuticals filings document the regulatory disclosures of a Delaware biopharmaceutical company focused on generic and proprietary injectable, inhalation, and intranasal products, along with active pharmaceutical ingredient products. Form 8-K reports furnish operating results, product revenue commentary, non-GAAP measures, and material business updates tied to the company's pharmaceutical products business.
Amphastar's SEC filings also cover governance and capital-structure matters, including proxy disclosures, executive compensation, employment agreements, equity-compensation dilution, and share repurchase authorizations. Material agreement filings describe licensing rights for a corticotropin compound, supply arrangements involving a Chinese subsidiary, related-party review procedures, and commercial terms that affect the company's pipeline, manufacturing, and distribution activities.
Amphastar Pharmaceuticals director Diane G. Gerst received equity compensation consisting of 8,143 shares of common stock in the form of restricted stock units and a stock option for 17,365 shares at an exercise price of $18.42 per share. All RSUs and option shares vest on June 1, 2027. Following these awards, she directly holds 31,899 shares of common stock.
Amphastar Pharmaceuticals director David Russell Gaugh received new equity awards as part of his compensation. He was granted 8,143 shares of Common Stock in the form of restricted stock units, which fully vest on June 1, 2027. Following this grant, he directly holds 14,447 Common Stock shares. He was also awarded stock options covering 17,365 shares of Common Stock at an exercise price of $18.42 per share. All of these options vest on June 1, 2027 and expire on June 1, 2036, giving him the right to buy shares at that fixed price if the company performs well over time.
Amphastar Pharmaceuticals director Deflin Gayle received new equity compensation awards. On June 1, 2026, Gayle acquired 8,143 shares of Common Stock through restricted stock units that vest on June 1, 2027. Gayle also received stock options for 17,365 shares at an exercise price of $18.42 per share, with all option shares vesting on June 1, 2027 and expiring on June 1, 2036. Following the stock grant, Gayle directly holds 19,057 shares of Common Stock, in addition to the newly granted options. These are compensation-related awards rather than open-market purchases or sales.
Amphastar Pharmaceuticals, Inc. reported results from its annual stockholder meeting. Stockholders elected three directors — David Gaugh, William J. Peters, and Jacob Liawatidewi — to serve until the 2029 annual meeting. They also ratified Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2026.
Stockholders approved, on a non-binding basis, the compensation of the company’s named executive officers. In a separate advisory vote, stockholders indicated a preference for holding say‑on‑pay votes every year, and the board decided to schedule future advisory votes on executive compensation annually, with the next required frequency vote to occur no later than the 2032 annual meeting.
Amphastar Pharmaceuticals reported sharply lower profitability for the quarter ended March 31, 2026 despite essentially flat sales. Net revenues were $171.2 million versus $170.5 million a year earlier, but net income fell to $6.4 million from $25.3 million as cost of revenues and operating expenses increased.
Gross profit declined to $70.3 million from $85.3 million, while research and development, general and administrative, and other costs all rose. Diluted earnings per share were $0.14 compared with $0.51. Operating cash flow improved to $47.8 million, and the company ended the quarter with $171.2 million in cash, cash equivalents, and restricted cash and total assets of $1.65 billion, including significant BAQSIMI® product rights.
Amphastar Pharmaceuticals reported first quarter 2026 results showing flat revenue but significantly lower profit. Net revenues were $171.2 million, essentially unchanged from $170.5 million a year earlier, while GAAP net income fell to $6.4 million from $25.3 million. GAAP diluted EPS declined to $0.14 from $0.51, and adjusted non-GAAP diluted EPS decreased to $0.42 from $0.74.
Gross profit dropped to $70.3 million from $85.3 million as gross margin narrowed to 41.1% from 50.0%, reflecting an 18% rise in cost of revenues. Research and development spending increased 33% to $26.7 million and general and administrative expense rose 13% to $18.0 million. Despite lower earnings, cash flow provided by operating activities was $47.8 million.
The company highlighted the approval and launch of Ipratropium Bromide HFA, an exclusive license for a fully synthetic corticotropin compound, and progress across a proprietary and biosimilar pipeline. Current filings include one ANDA and one biosimilar insulin candidate targeting markets over $1.6 billion, plus additional biosimilar and generic programs addressing several billion dollars of estimated market opportunity.
Amphastar Pharmaceuticals, Inc. is holding a virtual 2026 annual stockholder meeting on June 1, 2026 at 11:30 a.m. Pacific Time. Stockholders of record as of April 6, 2026, when 44,534,974 common shares were outstanding, can vote online, by phone, or by mail.
Investors will vote on electing three Class I directors to terms ending in 2029, ratifying Ernst & Young LLP as independent auditor for 2026, approving an advisory “say‑on‑pay” vote on executive compensation, and choosing how often future say‑on‑pay votes occur. The board recommends annual say‑on‑pay votes and supports all four proposals.
Amphastar Pharmaceuticals Inc received an amended Schedule 13G/A from The Vanguard Group reporting that Vanguard beneficially owns 0 shares of Amphastar common stock as disclosed in the amendment dated 03/13/2026 and signed 03/26/2026.
The filing explains this zero ownership reflects an internal realignment at The Vanguard Group, Inc.; certain subsidiaries or business divisions now report beneficial ownership separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The amendment lists Vanguard's voting and dispositive powers as 0 and states Vanguard's aggregate ownership is 0% of the class.
Amphastar Pharmaceuticals director and EVP Liawatidewi Yakob reported a tax-withholding share disposition related to RSU vesting. On 2026-03-15, 1,033 shares of Common Stock were withheld at $18.18 per share to cover her tax liability from vested restricted stock units.
After this non-market tax-withholding event, she directly holds 121,892 shares of Amphastar Common Stock. An additional 2,459 shares are held indirectly by the Yakob and Sunmoon Trust dated July 25, 2013, for which she serves as a trustee.